XML 173 R25.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Results for the year - Segment information - Geographical Areas (Details) - DKK (kr)
kr in Millions
 12 Months Ended
Dec. 31, 2019
Dec. 31, 2018
Dec. 31, 2017
Disclosure of geographical areas [line items]      
Total net sales kr 122,021 kr 111,831 kr 111,696
Property, plant and equipment 50,551 41,891  
Total assets 125,612 110,769 102,355
International Operations      
Disclosure of geographical areas [line items]      
Total net sales kr 61,564 kr 54,923 kr 53,687
Total sales growth as reported (as a percent) 12.10% 2.30% 2.20%
Property, plant and equipment kr 30,972 kr 28,851 kr 27,929
Trade receivables 10,508 9,884 9,423
Allowance for doubtful trade receivables (1,471) (1,358) (1,262)
Total assets 85,541 80,420 81,743
International Operations | Diabetes and Obesity care total      
Disclosure of geographical areas [line items]      
Total net sales 50,271 44,334 43,023
International Operations | Diabetes and Obesity care total | Long-acting insulin      
Disclosure of geographical areas [line items]      
Total net sales 9,035 7,942 7,416
International Operations | Diabetes and Obesity care total | Tresiba      
Disclosure of geographical areas [line items]      
Total net sales 3,477 2,764 2,345
International Operations | Diabetes and Obesity care total | Xultophy      
Disclosure of geographical areas [line items]      
Total net sales 1,493 1,085 567
International Operations | Diabetes and Obesity care total | Levemir      
Disclosure of geographical areas [line items]      
Total net sales 4,065 4,093 4,504
International Operations | Diabetes and Obesity care total | Premix insulin      
Disclosure of geographical areas [line items]      
Total net sales 9,707 8,862 8,959
International Operations | Diabetes and Obesity care total | Ryzodeg      
Disclosure of geographical areas [line items]      
Total net sales 993 714 492
International Operations | Diabetes and Obesity care total | NovoRapid/NovoLog      
Disclosure of geographical areas [line items]      
Total net sales 8,714 8,148 8,467
International Operations | Diabetes and Obesity care total | Fast-acting insulin      
Disclosure of geographical areas [line items]      
Total net sales 10,304 9,332 9,156
International Operations | Diabetes and Obesity care total | Fiasp      
Disclosure of geographical areas [line items]      
Total net sales 617 357 91
International Operations | Diabetes and Obesity care total | U17 NovoLog/NovoRapid      
Disclosure of geographical areas [line items]      
Total net sales 9,687 8,975 9,065
International Operations | Diabetes and Obesity care total | Human insulin      
Disclosure of geographical areas [line items]      
Total net sales 7,361 7,348 7,856
International Operations | Diabetes and Obesity care total | Total insulin      
Disclosure of geographical areas [line items]      
Total net sales 36,407 33,484 33,387
International Operations | Diabetes and Obesity care total | Total GLP-1      
Disclosure of geographical areas [line items]      
Total net sales 8,392 6,279 5,708
International Operations | Diabetes and Obesity care total | Victoza      
Disclosure of geographical areas [line items]      
Total net sales 7,249 6,240 5,708
International Operations | Diabetes and Obesity care total | Ozempic      
Disclosure of geographical areas [line items]      
Total net sales 1,143 39 0
International Operations | Diabetes and Obesity care total | Rybelsus      
Disclosure of geographical areas [line items]      
Total net sales 0 0 0
International Operations | Diabetes and Obesity care total | Other Diabetes care      
Disclosure of geographical areas [line items]      
Total net sales 3,389 3,360 3,359
International Operations | Diabetes and Obesity care total | Total Diabetes care      
Disclosure of geographical areas [line items]      
Total net sales 48,188 43,123 42,454
International Operations | Diabetes and Obesity care total | Obesity care (Saxenda)      
Disclosure of geographical areas [line items]      
Total net sales 2,083 1,211 569
International Operations | Biopharm total      
Disclosure of geographical areas [line items]      
Total net sales 11,293 10,589 10,664
International Operations | Biopharm total | Haemophilia      
Disclosure of geographical areas [line items]      
Total net sales 5,946 5,572 5,446
International Operations | Biopharm total | NovoSeven      
Disclosure of geographical areas [line items]      
Total net sales 4,502 4,424 4,597
International Operations | Biopharm total | NovoEight      
Disclosure of geographical areas [line items]      
Total net sales 1,143 1,046 788
International Operations | Biopharm total | Growth disorders      
Disclosure of geographical areas [line items]      
Total net sales 4,225 4,000 4,105
International Operations | Biopharm total | Other Biopharm      
Disclosure of geographical areas [line items]      
Total net sales 1,122 1,017 1,113
Region Europe      
Disclosure of geographical areas [line items]      
Total net sales kr 23,262 kr 21,679 kr 21,189
Total sales growth as reported (as a percent) 7.30% 2.30% 2.50%
Property, plant and equipment kr 26,730 kr 25,500 kr 24,665
Trade receivables 3,611 3,388 3,273
Allowance for doubtful trade receivables (196) (241) (223)
Total assets 67,007 64,327 65,600
Region Europe | Diabetes and Obesity care total      
Disclosure of geographical areas [line items]      
Total net sales 18,255 16,666 16,067
Region Europe | Diabetes and Obesity care total | Long-acting insulin      
Disclosure of geographical areas [line items]      
Total net sales 4,720 4,282 3,895
Region Europe | Diabetes and Obesity care total | Tresiba      
Disclosure of geographical areas [line items]      
Total net sales 1,685 1,246 966
Region Europe | Diabetes and Obesity care total | Xultophy      
Disclosure of geographical areas [line items]      
Total net sales 1,266 1,007 560
Region Europe | Diabetes and Obesity care total | Levemir      
Disclosure of geographical areas [line items]      
Total net sales 1,769 2,029 2,369
Region Europe | Diabetes and Obesity care total | Premix insulin      
Disclosure of geographical areas [line items]      
Total net sales 1,595 1,701 1,878
Region Europe | Diabetes and Obesity care total | Ryzodeg      
Disclosure of geographical areas [line items]      
Total net sales 68 56 26
Region Europe | Diabetes and Obesity care total | NovoRapid/NovoLog      
Disclosure of geographical areas [line items]      
Total net sales 1,527 1,645 1,852
Region Europe | Diabetes and Obesity care total | Fast-acting insulin      
Disclosure of geographical areas [line items]      
Total net sales 4,732 4,558 4,366
Region Europe | Diabetes and Obesity care total | Fiasp      
Disclosure of geographical areas [line items]      
Total net sales 585 357 91
Region Europe | Diabetes and Obesity care total | U17 NovoLog/NovoRapid      
Disclosure of geographical areas [line items]      
Total net sales 4,147 4,201 4,275
Region Europe | Diabetes and Obesity care total | Human insulin      
Disclosure of geographical areas [line items]      
Total net sales 1,380 1,580 1,770
Region Europe | Diabetes and Obesity care total | Total insulin      
Disclosure of geographical areas [line items]      
Total net sales 12,427 12,121 11,909
Region Europe | Diabetes and Obesity care total | Total GLP-1      
Disclosure of geographical areas [line items]      
Total net sales 4,932 3,759 3,451
Region Europe | Diabetes and Obesity care total | Victoza      
Disclosure of geographical areas [line items]      
Total net sales 3,967 3,720 3,451
Region Europe | Diabetes and Obesity care total | Ozempic      
Disclosure of geographical areas [line items]      
Total net sales 965 39 0
Region Europe | Diabetes and Obesity care total | Rybelsus      
Disclosure of geographical areas [line items]      
Total net sales 0 0 0
Region Europe | Diabetes and Obesity care total | Other Diabetes care      
Disclosure of geographical areas [line items]      
Total net sales 562 579 605
Region Europe | Diabetes and Obesity care total | Total Diabetes care      
Disclosure of geographical areas [line items]      
Total net sales 17,921 16,459 15,965
Region Europe | Diabetes and Obesity care total | Obesity care (Saxenda)      
Disclosure of geographical areas [line items]      
Total net sales 334 207 102
Region Europe | Biopharm total      
Disclosure of geographical areas [line items]      
Total net sales 5,007 5,013 5,122
Region Europe | Biopharm total | Haemophilia      
Disclosure of geographical areas [line items]      
Total net sales 2,762 2,781 2,828
Region Europe | Biopharm total | NovoSeven      
Disclosure of geographical areas [line items]      
Total net sales 1,767 1,944 2,245
Region Europe | Biopharm total | NovoEight      
Disclosure of geographical areas [line items]      
Total net sales 790 776 551
Region Europe | Biopharm total | Growth disorders      
Disclosure of geographical areas [line items]      
Total net sales 1,466 1,511 1,572
Region Europe | Biopharm total | Other Biopharm      
Disclosure of geographical areas [line items]      
Total net sales 779 721 722
Region AAMEO      
Disclosure of geographical areas [line items]      
Total net sales kr 14,089 kr 12,153 kr 12,018
Total sales growth as reported (as a percent) 15.90% 1.10% 3.80%
Property, plant and equipment kr 1,003 kr 723 kr 566
Trade receivables 3,595 3,237 3,468
Allowance for doubtful trade receivables (967) (866) (823)
Total assets 6,729 5,635 5,876
Region AAMEO | Diabetes and Obesity care total      
Disclosure of geographical areas [line items]      
Total net sales 11,841 10,080 9,900
Region AAMEO | Diabetes and Obesity care total | Long-acting insulin      
Disclosure of geographical areas [line items]      
Total net sales 1,526 1,281 1,229
Region AAMEO | Diabetes and Obesity care total | Tresiba      
Disclosure of geographical areas [line items]      
Total net sales 406 337 261
Region AAMEO | Diabetes and Obesity care total | Xultophy      
Disclosure of geographical areas [line items]      
Total net sales 146 58 7
Region AAMEO | Diabetes and Obesity care total | Levemir      
Disclosure of geographical areas [line items]      
Total net sales 974 886 961
Region AAMEO | Diabetes and Obesity care total | Premix insulin      
Disclosure of geographical areas [line items]      
Total net sales 2,961 2,606 2,686
Region AAMEO | Diabetes and Obesity care total | Ryzodeg      
Disclosure of geographical areas [line items]      
Total net sales 429 275 183
Region AAMEO | Diabetes and Obesity care total | NovoRapid/NovoLog      
Disclosure of geographical areas [line items]      
Total net sales 2,532 2,331 2,503
Region AAMEO | Diabetes and Obesity care total | Fast-acting insulin      
Disclosure of geographical areas [line items]      
Total net sales 2,622 2,194 2,261
Region AAMEO | Diabetes and Obesity care total | Fiasp      
Disclosure of geographical areas [line items]      
Total net sales 27 0 0
Region AAMEO | Diabetes and Obesity care total | U17 NovoLog/NovoRapid      
Disclosure of geographical areas [line items]      
Total net sales 2,595 2,194 2,261
Region AAMEO | Diabetes and Obesity care total | Human insulin      
Disclosure of geographical areas [line items]      
Total net sales 2,230 2,065 1,922
Region AAMEO | Diabetes and Obesity care total | Total insulin      
Disclosure of geographical areas [line items]      
Total net sales 9,339 8,146 8,098
Region AAMEO | Diabetes and Obesity care total | Total GLP-1      
Disclosure of geographical areas [line items]      
Total net sales 1,009 841 858
Region AAMEO | Diabetes and Obesity care total | Victoza      
Disclosure of geographical areas [line items]      
Total net sales 1,005 841 858
Region AAMEO | Diabetes and Obesity care total | Ozempic      
Disclosure of geographical areas [line items]      
Total net sales 4 0 0
Region AAMEO | Diabetes and Obesity care total | Rybelsus      
Disclosure of geographical areas [line items]      
Total net sales 0 0 0
Region AAMEO | Diabetes and Obesity care total | Other Diabetes care      
Disclosure of geographical areas [line items]      
Total net sales 691 675 754
Region AAMEO | Diabetes and Obesity care total | Total Diabetes care      
Disclosure of geographical areas [line items]      
Total net sales 11,039 9,662 9,710
Region AAMEO | Diabetes and Obesity care total | Obesity care (Saxenda)      
Disclosure of geographical areas [line items]      
Total net sales 802 418 190
Region AAMEO | Biopharm total      
Disclosure of geographical areas [line items]      
Total net sales 2,248 2,073 2,118
Region AAMEO | Biopharm total | Haemophilia      
Disclosure of geographical areas [line items]      
Total net sales 1,305 1,177 1,163
Region AAMEO | Biopharm total | NovoSeven      
Disclosure of geographical areas [line items]      
Total net sales 1,130 1,049 1,097
Region AAMEO | Biopharm total | NovoEight      
Disclosure of geographical areas [line items]      
Total net sales 146 109 52
Region AAMEO | Biopharm total | Growth disorders      
Disclosure of geographical areas [line items]      
Total net sales 691 680 676
Region AAMEO | Biopharm total | Other Biopharm      
Disclosure of geographical areas [line items]      
Total net sales 252 216 279
Region China      
Disclosure of geographical areas [line items]      
Total net sales kr 12,844 kr 11,285 kr 10,709
Total sales growth as reported (as a percent) 13.80% 5.40% 2.40%
Property, plant and equipment kr 2,101 kr 1,812 kr 1,884
Trade receivables 1,760 1,841 1,541
Allowance for doubtful trade receivables 0 0 0
Total assets 6,820 6,003 5,927
Region China | Diabetes and Obesity care total      
Disclosure of geographical areas [line items]      
Total net sales 12,519 11,062 10,473
Region China | Diabetes and Obesity care total | Long-acting insulin      
Disclosure of geographical areas [line items]      
Total net sales 1,059 814 694
Region China | Diabetes and Obesity care total | Tresiba      
Disclosure of geographical areas [line items]      
Total net sales 87 16 2
Region China | Diabetes and Obesity care total | Xultophy      
Disclosure of geographical areas [line items]      
Total net sales 0 0 0
Region China | Diabetes and Obesity care total | Levemir      
Disclosure of geographical areas [line items]      
Total net sales 972 798 692
Region China | Diabetes and Obesity care total | Premix insulin      
Disclosure of geographical areas [line items]      
Total net sales 4,306 3,783 3,555
Region China | Diabetes and Obesity care total | Ryzodeg      
Disclosure of geographical areas [line items]      
Total net sales 4 0 0
Region China | Diabetes and Obesity care total | NovoRapid/NovoLog      
Disclosure of geographical areas [line items]      
Total net sales 4,302 3,783 3,555
Region China | Diabetes and Obesity care total | Fast-acting insulin      
Disclosure of geographical areas [line items]      
Total net sales 1,753 1,450 1,253
Region China | Diabetes and Obesity care total | Fiasp      
Disclosure of geographical areas [line items]      
Total net sales 0 0 0
Region China | Diabetes and Obesity care total | U17 NovoLog/NovoRapid      
Disclosure of geographical areas [line items]      
Total net sales 1,753 1,450 1,253
Region China | Diabetes and Obesity care total | Human insulin      
Disclosure of geographical areas [line items]      
Total net sales 2,847 2,821 3,096
Region China | Diabetes and Obesity care total | Total insulin      
Disclosure of geographical areas [line items]      
Total net sales 9,965 8,868 8,598
Region China | Diabetes and Obesity care total | Total GLP-1      
Disclosure of geographical areas [line items]      
Total net sales 898 521 309
Region China | Diabetes and Obesity care total | Victoza      
Disclosure of geographical areas [line items]      
Total net sales 898 521 309
Region China | Diabetes and Obesity care total | Ozempic      
Disclosure of geographical areas [line items]      
Total net sales 0 0 0
Region China | Diabetes and Obesity care total | Rybelsus      
Disclosure of geographical areas [line items]      
Total net sales 0 0 0
Region China | Diabetes and Obesity care total | Other Diabetes care      
Disclosure of geographical areas [line items]      
Total net sales 1,647 1,672 1,566
Region China | Diabetes and Obesity care total | Total Diabetes care      
Disclosure of geographical areas [line items]      
Total net sales 12,510 11,061 10,473
Region China | Diabetes and Obesity care total | Obesity care (Saxenda)      
Disclosure of geographical areas [line items]      
Total net sales 9 1 0
Region China | Biopharm total      
Disclosure of geographical areas [line items]      
Total net sales 325 223 236
Region China | Biopharm total | Haemophilia      
Disclosure of geographical areas [line items]      
Total net sales 284 199 216
Region China | Biopharm total | NovoSeven      
Disclosure of geographical areas [line items]      
Total net sales 269 194 215
Region China | Biopharm total | NovoEight      
Disclosure of geographical areas [line items]      
Total net sales 15 5 1
Region China | Biopharm total | Growth disorders      
Disclosure of geographical areas [line items]      
Total net sales 36 20 15
Region China | Biopharm total | Other Biopharm      
Disclosure of geographical areas [line items]      
Total net sales 5 4 5
Region Japan & Korea      
Disclosure of geographical areas [line items]      
Total net sales kr 6,453 kr 5,797 kr 6,072
Total sales growth as reported (as a percent) 11.30% (4.50%) (2.50%)
Property, plant and equipment kr 436 kr 201 kr 146
Trade receivables 495 504 279
Allowance for doubtful trade receivables (7) (5) (5)
Total assets 1,543 1,503 1,304
Region Japan & Korea | Diabetes and Obesity care total      
Disclosure of geographical areas [line items]      
Total net sales 4,063 3,630 3,708
Region Japan & Korea | Diabetes and Obesity care total | Long-acting insulin      
Disclosure of geographical areas [line items]      
Total net sales 930 857 872
Region Japan & Korea | Diabetes and Obesity care total | Tresiba      
Disclosure of geographical areas [line items]      
Total net sales 821 751 739
Region Japan & Korea | Diabetes and Obesity care total | Xultophy      
Disclosure of geographical areas [line items]      
Total net sales 11 0 0
Region Japan & Korea | Diabetes and Obesity care total | Levemir      
Disclosure of geographical areas [line items]      
Total net sales 98 106 133
Region Japan & Korea | Diabetes and Obesity care total | Premix insulin      
Disclosure of geographical areas [line items]      
Total net sales 722 650 697
Region Japan & Korea | Diabetes and Obesity care total | Ryzodeg      
Disclosure of geographical areas [line items]      
Total net sales 457 351 253
Region Japan & Korea | Diabetes and Obesity care total | NovoRapid/NovoLog      
Disclosure of geographical areas [line items]      
Total net sales 265 299 444
Region Japan & Korea | Diabetes and Obesity care total | Fast-acting insulin      
Disclosure of geographical areas [line items]      
Total net sales 790 779 941
Region Japan & Korea | Diabetes and Obesity care total | Fiasp      
Disclosure of geographical areas [line items]      
Total net sales 5 0 0
Region Japan & Korea | Diabetes and Obesity care total | U17 NovoLog/NovoRapid      
Disclosure of geographical areas [line items]      
Total net sales 785 779 941
Region Japan & Korea | Diabetes and Obesity care total | Human insulin      
Disclosure of geographical areas [line items]      
Total net sales 170 187 232
Region Japan & Korea | Diabetes and Obesity care total | Total insulin      
Disclosure of geographical areas [line items]      
Total net sales 2,612 2,473 2,742
Region Japan & Korea | Diabetes and Obesity care total | Total GLP-1      
Disclosure of geographical areas [line items]      
Total net sales 748 614 590
Region Japan & Korea | Diabetes and Obesity care total | Victoza      
Disclosure of geographical areas [line items]      
Total net sales 748 614 590
Region Japan & Korea | Diabetes and Obesity care total | Ozempic      
Disclosure of geographical areas [line items]      
Total net sales 0 0 0
Region Japan & Korea | Diabetes and Obesity care total | Rybelsus      
Disclosure of geographical areas [line items]      
Total net sales 0 0 0
Region Japan & Korea | Diabetes and Obesity care total | Other Diabetes care      
Disclosure of geographical areas [line items]      
Total net sales 421 368 376
Region Japan & Korea | Diabetes and Obesity care total | Total Diabetes care      
Disclosure of geographical areas [line items]      
Total net sales 3,781 3,455 3,708
Region Japan & Korea | Diabetes and Obesity care total | Obesity care (Saxenda)      
Disclosure of geographical areas [line items]      
Total net sales 282 175 0
Region Japan & Korea | Biopharm total      
Disclosure of geographical areas [line items]      
Total net sales 2,390 2,167 2,364
Region Japan & Korea | Biopharm total | Haemophilia      
Disclosure of geographical areas [line items]      
Total net sales 560 557 681
Region Japan & Korea | Biopharm total | NovoSeven      
Disclosure of geographical areas [line items]      
Total net sales 377 400 497
Region Japan & Korea | Biopharm total | NovoEight      
Disclosure of geographical areas [line items]      
Total net sales 116 135 169
Region Japan & Korea | Biopharm total | Growth disorders      
Disclosure of geographical areas [line items]      
Total net sales 1,746 1,538 1,579
Region Japan & Korea | Biopharm total | Other Biopharm      
Disclosure of geographical areas [line items]      
Total net sales 84 72 104
Region Latin America      
Disclosure of geographical areas [line items]      
Total net sales kr 4,916 kr 4,009 kr 3,699
Total sales growth as reported (as a percent) 22.60% 8.40% 3.00%
Property, plant and equipment kr 702 kr 615 kr 668
Trade receivables 1,047 914 862
Allowance for doubtful trade receivables (301) (246) (211)
Total assets 3,442 2,952 3,036
Region Latin America | Diabetes and Obesity care total      
Disclosure of geographical areas [line items]      
Total net sales 3,593 2,896 2,875
Region Latin America | Diabetes and Obesity care total | Long-acting insulin      
Disclosure of geographical areas [line items]      
Total net sales 800 708 726
Region Latin America | Diabetes and Obesity care total | Tresiba      
Disclosure of geographical areas [line items]      
Total net sales 478 414 377
Region Latin America | Diabetes and Obesity care total | Xultophy      
Disclosure of geographical areas [line items]      
Total net sales 70 20 0
Region Latin America | Diabetes and Obesity care total | Levemir      
Disclosure of geographical areas [line items]      
Total net sales 252 274 349
Region Latin America | Diabetes and Obesity care total | Premix insulin      
Disclosure of geographical areas [line items]      
Total net sales 123 122 143
Region Latin America | Diabetes and Obesity care total | Ryzodeg      
Disclosure of geographical areas [line items]      
Total net sales 35 32 30
Region Latin America | Diabetes and Obesity care total | NovoRapid/NovoLog      
Disclosure of geographical areas [line items]      
Total net sales 88 90 113
Region Latin America | Diabetes and Obesity care total | Fast-acting insulin      
Disclosure of geographical areas [line items]      
Total net sales 407 351 335
Region Latin America | Diabetes and Obesity care total | Fiasp      
Disclosure of geographical areas [line items]      
Total net sales 0 0 0
Region Latin America | Diabetes and Obesity care total | U17 NovoLog/NovoRapid      
Disclosure of geographical areas [line items]      
Total net sales 407 351 335
Region Latin America | Diabetes and Obesity care total | Human insulin      
Disclosure of geographical areas [line items]      
Total net sales 734 695 836
Region Latin America | Diabetes and Obesity care total | Total insulin      
Disclosure of geographical areas [line items]      
Total net sales 2,064 1,876 2,040
Region Latin America | Diabetes and Obesity care total | Total GLP-1      
Disclosure of geographical areas [line items]      
Total net sales 805 544 500
Region Latin America | Diabetes and Obesity care total | Victoza      
Disclosure of geographical areas [line items]      
Total net sales 631 544 500
Region Latin America | Diabetes and Obesity care total | Ozempic      
Disclosure of geographical areas [line items]      
Total net sales 174 0 0
Region Latin America | Diabetes and Obesity care total | Rybelsus      
Disclosure of geographical areas [line items]      
Total net sales 0 0 0
Region Latin America | Diabetes and Obesity care total | Other Diabetes care      
Disclosure of geographical areas [line items]      
Total net sales 68 66 58
Region Latin America | Diabetes and Obesity care total | Total Diabetes care      
Disclosure of geographical areas [line items]      
Total net sales 2,937 2,486 2,598
Region Latin America | Diabetes and Obesity care total | Obesity care (Saxenda)      
Disclosure of geographical areas [line items]      
Total net sales 656 410 277
Region Latin America | Biopharm total      
Disclosure of geographical areas [line items]      
Total net sales 1,323 1,113 824
Region Latin America | Biopharm total | Haemophilia      
Disclosure of geographical areas [line items]      
Total net sales 1,035 858 558
Region Latin America | Biopharm total | NovoSeven      
Disclosure of geographical areas [line items]      
Total net sales 959 837 543
Region Latin America | Biopharm total | NovoEight      
Disclosure of geographical areas [line items]      
Total net sales 76 21 15
Region Latin America | Biopharm total | Growth disorders      
Disclosure of geographical areas [line items]      
Total net sales 286 251 263
Region Latin America | Biopharm total | Other Biopharm      
Disclosure of geographical areas [line items]      
Total net sales 2 4 3
North America Operations      
Disclosure of geographical areas [line items]      
Total net sales kr 60,457 kr 56,908 kr 58,009
Total sales growth as reported (as a percent) 6.20% (1.90%) (2.10%)
Property, plant and equipment kr 19,579 kr 13,040 kr 7,318
Trade receivables 14,404 12,902 10,742
Allowance for doubtful trade receivables (13) (12) (32)
Total assets 40,071 30,349 20,612
North America Operations | Diabetes and Obesity care total      
Disclosure of geographical areas [line items]      
Total net sales 52,569 49,570 49,854
North America Operations | Diabetes and Obesity care total | Long-acting insulin      
Disclosure of geographical areas [line items]      
Total net sales 11,741 12,902 14,758
North America Operations | Diabetes and Obesity care total | Tresiba      
Disclosure of geographical areas [line items]      
Total net sales 5,782 5,271 4,982
North America Operations | Diabetes and Obesity care total | Xultophy      
Disclosure of geographical areas [line items]      
Total net sales 717 529 162
North America Operations | Diabetes and Obesity care total | Levemir      
Disclosure of geographical areas [line items]      
Total net sales 5,242 7,102 9,614
North America Operations | Diabetes and Obesity care total | Premix insulin      
Disclosure of geographical areas [line items]      
Total net sales 871 1,332 1,790
North America Operations | Diabetes and Obesity care total | Ryzodeg      
Disclosure of geographical areas [line items]      
Total net sales 0 0 0
North America Operations | Diabetes and Obesity care total | NovoRapid/NovoLog      
Disclosure of geographical areas [line items]      
Total net sales 871 1,332 1,790
North America Operations | Diabetes and Obesity care total | Fast-acting insulin      
Disclosure of geographical areas [line items]      
Total net sales 8,999 10,021 10,968
North America Operations | Diabetes and Obesity care total | Fiasp      
Disclosure of geographical areas [line items]      
Total net sales 626 233 8
North America Operations | Diabetes and Obesity care total | U17 NovoLog/NovoRapid      
Disclosure of geographical areas [line items]      
Total net sales 8,373 9,788 10,960
North America Operations | Diabetes and Obesity care total | Human insulin      
Disclosure of geographical areas [line items]      
Total net sales 1,675 1,917 1,937
North America Operations | Diabetes and Obesity care total | Total insulin      
Disclosure of geographical areas [line items]      
Total net sales 23,286 26,172 29,453
North America Operations | Diabetes and Obesity care total | Total GLP-1      
Disclosure of geographical areas [line items]      
Total net sales 24,829 19,850 17,465
North America Operations | Diabetes and Obesity care total | Victoza      
Disclosure of geographical areas [line items]      
Total net sales 14,685 18,093 17,465
North America Operations | Diabetes and Obesity care total | Ozempic      
Disclosure of geographical areas [line items]      
Total net sales 10,094 1,757 0
North America Operations | Diabetes and Obesity care total | Rybelsus      
Disclosure of geographical areas [line items]      
Total net sales 50 0 0
North America Operations | Diabetes and Obesity care total | Other Diabetes care      
Disclosure of geographical areas [line items]      
Total net sales 858 890 943
North America Operations | Diabetes and Obesity care total | Total Diabetes care      
Disclosure of geographical areas [line items]      
Total net sales 48,973 46,912 47,861
North America Operations | Diabetes and Obesity care total | Obesity care (Saxenda)      
Disclosure of geographical areas [line items]      
Total net sales 3,596 2,658 1,993
North America Operations | Biopharm total      
Disclosure of geographical areas [line items]      
Total net sales 7,888 7,338 8,155
North America Operations | Biopharm total | Haemophilia      
Disclosure of geographical areas [line items]      
Total net sales 4,335 4,004 5,023
North America Operations | Biopharm total | NovoSeven      
Disclosure of geographical areas [line items]      
Total net sales 3,617 3,457 4,609
North America Operations | Biopharm total | NovoEight      
Disclosure of geographical areas [line items]      
Total net sales 382 308 315
North America Operations | Biopharm total | Growth disorders      
Disclosure of geographical areas [line items]      
Total net sales 3,050 2,834 2,550
North America Operations | Biopharm total | Other Biopharm      
Disclosure of geographical areas [line items]      
Total net sales 503 500 582
Region USA      
Disclosure of geographical areas [line items]      
Total net sales kr 57,486 kr 54,488 kr 55,831
Total sales growth as reported (as a percent) 5.50% (2.40%) (2.40%)
Property, plant and equipment kr 19,531 kr 13,023 kr 7,298
Trade receivables 13,999 12,643 10,517
Allowance for doubtful trade receivables (13) (12) (32)
Total assets 39,460 29,732 20,180
Region USA | Diabetes and Obesity care total      
Disclosure of geographical areas [line items]      
Total net sales 50,173 47,680 48,088
Region USA | Diabetes and Obesity care total | Long-acting insulin      
Disclosure of geographical areas [line items]      
Total net sales 11,271 12,600 14,466
Region USA | Diabetes and Obesity care total | Tresiba      
Disclosure of geographical areas [line items]      
Total net sales 5,500 5,192 4,970
Region USA | Diabetes and Obesity care total | Xultophy      
Disclosure of geographical areas [line items]      
Total net sales 708 528 162
Region USA | Diabetes and Obesity care total | Levemir      
Disclosure of geographical areas [line items]      
Total net sales 5,063 6,880 9,334
Region USA | Diabetes and Obesity care total | Premix insulin      
Disclosure of geographical areas [line items]      
Total net sales 839 1,294 1,743
Region USA | Diabetes and Obesity care total | Ryzodeg      
Disclosure of geographical areas [line items]      
Total net sales 0 0 0
Region USA | Diabetes and Obesity care total | NovoRapid/NovoLog      
Disclosure of geographical areas [line items]      
Total net sales 839 1,294 1,743
Region USA | Diabetes and Obesity care total | Fast-acting insulin      
Disclosure of geographical areas [line items]      
Total net sales 8,592 9,634 10,574
Region USA | Diabetes and Obesity care total | Fiasp      
Disclosure of geographical areas [line items]      
Total net sales 597 211 0
Region USA | Diabetes and Obesity care total | U17 NovoLog/NovoRapid      
Disclosure of geographical areas [line items]      
Total net sales 7,995 9,423 10,574
Region USA | Diabetes and Obesity care total | Human insulin      
Disclosure of geographical areas [line items]      
Total net sales 1,552 1,778 1,766
Region USA | Diabetes and Obesity care total | Total insulin      
Disclosure of geographical areas [line items]      
Total net sales 22,254 25,306 28,549
Region USA | Diabetes and Obesity care total | Total GLP-1      
Disclosure of geographical areas [line items]      
Total net sales 23,866 19,195 16,929
Region USA | Diabetes and Obesity care total | Victoza      
Disclosure of geographical areas [line items]      
Total net sales 14,217 17,561 16,929
Region USA | Diabetes and Obesity care total | Ozempic      
Disclosure of geographical areas [line items]      
Total net sales 9,599 1,634 0
Region USA | Diabetes and Obesity care total | Rybelsus      
Disclosure of geographical areas [line items]      
Total net sales 50 0 0
Region USA | Diabetes and Obesity care total | Other Diabetes care      
Disclosure of geographical areas [line items]      
Total net sales 705 733 782
Region USA | Diabetes and Obesity care total | Total Diabetes care      
Disclosure of geographical areas [line items]      
Total net sales 46,825 45,234 46,260
Region USA | Diabetes and Obesity care total | Obesity care (Saxenda)      
Disclosure of geographical areas [line items]      
Total net sales 3,348 2,446 1,828
Region USA | Biopharm total      
Disclosure of geographical areas [line items]      
Total net sales 7,313 6,808 7,743
Region USA | Biopharm total | Haemophilia      
Disclosure of geographical areas [line items]      
Total net sales 4,031 3,723 4,852
Region USA | Biopharm total | NovoSeven      
Disclosure of geographical areas [line items]      
Total net sales 3,454 3,278 4,451
Region USA | Biopharm total | NovoEight      
Disclosure of geographical areas [line items]      
Total net sales 358 291 315
Region USA | Biopharm total | Growth disorders      
Disclosure of geographical areas [line items]      
Total net sales 3,035 2,823 2,543
Region USA | Biopharm total | Other Biopharm      
Disclosure of geographical areas [line items]      
Total net sales kr 247 kr 262 kr 348